Just after halting a CYP3A4 inducer, as the consequences of the inducer decline, the fentanyl plasma concentration will increase which could improve or prolong each the therapeutic and adverse results.
pentobarbital will decrease the level or impact of larotrectinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will lessen the level or influence of fludrocortisone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
Keep an eye on Intently (one)pentobarbital will decrease the level or impact of benzhydrocodone/acetaminophen by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Intently. Warning when discontinuing CYP3A4 inducers that are coadministered with benzhydrocodone (prodrug of hydrocodone); plasma concentrations of hydrocodone may raise and may lead to possibly deadly respiratory depression.
With therapeutic doses of TCAs, barbiturates raise metabolism and decrease blood concentrations of TCAs.
Medicines that call for prior authorization. This restriction necessitates that specific clinical criteria be met just before the acceptance with the prescription.
pentobarbital will lessen the extent or result of zaleplon by impacting hepatic/intestinal 戊巴比妥鈉製作 enzyme CYP3A4 metabolism. Small/Significance Unknown.
pentobarbital will minimize the level or impact of tacrolimus by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
pentobarbital will decrease the extent or effect of terbinafine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
With therapeutic doses of TCAs, barbiturates improve metabolism and reduce blood concentrations of TCAs.
pentobarbital will lessen the extent or influence of alfentanil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unfamiliar.
Monitor Carefully (one)pentobarbital will reduce the extent or effect of fentanyl intranasal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Carefully. Coadministration of fentanyl with CYP3A4 inducers could lead on to a lessen in fentanyl plasma concentrations, not enough efficacy or, perhaps, enhancement of a withdrawal syndrome in a very patient that has made physical dependence to fentanyl. Soon after halting a CYP3A4 inducer, as the consequences from the inducer decrease, the fentanyl plasma focus will maximize which could improve or prolong equally the therapeutic and adverse consequences.
pentobarbital increases toxicity of methoxyflurane by increasing metabolism. Contraindicated. Increased metabolism of methoxyflurane to nephrotoxic compounds.
pentobarbital will lessen the extent or effect of alfuzosin by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unknown.